London · Delayed Price · Currency is GBP · Price in GBX ImmuPharma Company Description
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally.
It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology; and CDx, a companion diagnostic, which is in clinical trial for the identification of immune endotype and treatment of various autoimmune diseases.
The company is also involved in the development of Kapiglucagon, a proprietary glucagon prodrug, which is in pre-clinical trial for the treatment of type 1 diabetes; BioAMB, an amphotericin-B therapy, which is in pre-clinical trial for the treatment of invasive fungal infections, such as aspergillosis; and BioCIN, a vancomycin-based therapy, which is in pre-clinical trial for the treatment of gram-positive infections comprising methicillin-resistant staphylococcus aureus, sepsis, lower respiratory tract infections, osteomyelitis, and skin infections.
It has collaboration arrangements with Avion Pharmaceuticals LLC and Centre National de la Recherche Scientifique for the development of P140 platform.
The company was founded in 1999 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Timothy McCarthy |
Contact Details
Address: One Bartholomew Close London, EC1A 7BL United Kingdom | |
| Phone | 44 20 7206 2650 |
| Website | immupharma.co.uk |
Stock Details
| Ticker Symbol | IMM |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB0033711010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy McCarthy | Chief Executive Officer |
| Ashley Clarke | Chief Financial Officer |
| Timothy Franklin | Chief Operating Officer |
| Lisa Baderoon | Head of Investor Relations |